‘Cracks Show’ as CDRH Staff Contend With Heavy Workloads

Why It Matters

Longer review times delay market entry for innovative devices, affecting patient access and company revenue.

Key Takeaways

• Staff cuts reduce CDRH capacity
• Remaining employees face heavier case loads
• Decision reversals cause applicant uncertainty
• Approval timelines lengthening for medical devices
• Industry pressures HHS for resource restoration

Pulse Analysis

The Center for Devices and Radiological Health, the FDA’s hub for medical‑device oversight, has been operating with a leaner workforce since budget‑driven cuts took effect in 2023. Son Nguyen, special counsel at Cooley, highlighted that the agency’s staffing levels are now well below the numbers needed to process the growing volume of submissions. As a result, reviewers are juggling larger case loads, often handling multiple applications simultaneously. This pressure not only stretches individual capacity but also reduces the time available for thorough scientific evaluation, raising concerns about the quality and consistency of regulatory decisions.

For medtech companies, the staffing crunch translates into longer approval cycles and greater regulatory uncertainty. Applicants report mid‑application decision changes, forcing them to re‑submit data or adjust development plans mid‑stream. Such disruptions can inflate R&D costs, postpone revenue streams, and, in some cases, push products out of competitive windows. Investors monitor CDRH’s throughput closely, as delayed clearances can affect market valuations and merger‑acquisition timelines. Moreover, patients awaiting novel therapies may experience delayed access, underscoring the public‑health stakes of a strained review process.

Industry groups and individual firms are now lobbying Congress and HHS for additional resources, arguing that a well‑staffed CDRH is essential for maintaining the United States’ leadership in medical‑device innovation. Proposals include targeted hiring, temporary contractor boosts, and process‑automation investments to alleviate bottlenecks. While the agency has signaled intent to address the backlog, concrete funding commitments remain pending. Until staffing levels are restored, manufacturers should anticipate extended timelines and incorporate regulatory risk buffers into project plans. A stable, adequately resourced CDRH will be pivotal for sustaining growth in the medtech sector.